1. Atezolizumab was associated with non-significantly increased disease-free survival compared to placebo (57.2 months vs. 49.5 months). 2. Serious adverse ...
1. Objective response rate was not significantly different in patients treated with stereotactic body radiotherapy compared to those without. 2. ...
1. In this retrospective cohort study investigating targeted therapy of programmed cell death receptor 1 and programmed cell death ligand ...
1. Overall survival and progression-free survival were higher for patients on nivolumab plus chemotherapy compared to chemotherapy alone. 2. Severe ...
Click to read the study in The Lancet Oncology.
Click to read the study in The Lancet Oncology. Click to see previously reported survival outcomes from the same cohort.
Click to read the study in The Lancet Oncology.
Click to read the study in The Lancet Oncology.
1. Median overall survival and progression-free survival were significantly improved with cemiplimab monotherapy compared to chemotherapy. 2. Patients treated with ...
Click to read the study in Nature Communications
